UA105520C2 - Антитіла до людського tweak та їхнє застосування - Google Patents

Антитіла до людського tweak та їхнє застосування

Info

Publication number
UA105520C2
UA105520C2 UAA201112304A UAA201112304A UA105520C2 UA 105520 C2 UA105520 C2 UA 105520C2 UA A201112304 A UAA201112304 A UA A201112304A UA A201112304 A UAA201112304 A UA A201112304A UA 105520 C2 UA105520 C2 UA 105520C2
Authority
UA
Ukraine
Prior art keywords
antibodies against
against human
human tweak
tweak
binding
Prior art date
Application number
UAA201112304A
Other languages
English (en)
Russian (ru)
Inventor
Моніка Бенер
Хендрік Кньотген
Йєнс Нівьонер
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA105520C2 publication Critical patent/UA105520C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Винахід стосується антитіла, що зв'язується з TWEAK, фармацевтичної композиції, що містить це антитіло, та його застосування.
UAA201112304A 2009-04-02 2010-03-30 Антитіла до людського tweak та їхнє застосування UA105520C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02
PCT/EP2010/002009 WO2010115555A2 (en) 2009-04-02 2010-03-30 Antibodies against human tweak and uses thereof

Publications (1)

Publication Number Publication Date
UA105520C2 true UA105520C2 (uk) 2014-05-26

Family

ID=40673340

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201112304A UA105520C2 (uk) 2009-04-02 2010-03-30 Антитіла до людського tweak та їхнє застосування

Country Status (23)

Country Link
US (3) US8093006B2 (uk)
EP (2) EP2597104A1 (uk)
JP (1) JP5596777B2 (uk)
KR (1) KR101344611B1 (uk)
CN (1) CN102369219A (uk)
AR (1) AR076020A1 (uk)
AU (1) AU2010233997A1 (uk)
BR (1) BRPI1014867A2 (uk)
CA (1) CA2756245A1 (uk)
CL (1) CL2011002452A1 (uk)
CO (1) CO6362025A2 (uk)
CR (1) CR20110462A (uk)
EC (1) ECSP11011362A (uk)
IL (1) IL214355A0 (uk)
MA (1) MA33097B1 (uk)
MX (1) MX2011010117A (uk)
NZ (1) NZ594347A (uk)
PE (1) PE20120577A1 (uk)
RU (1) RU2011143903A (uk)
SG (2) SG175005A1 (uk)
TW (1) TWI423815B (uk)
UA (1) UA105520C2 (uk)
WO (1) WO2010115555A2 (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
SG188605A1 (en) 2010-10-05 2013-04-30 Hoffmann La Roche Antibodies against human tweak and uses thereof
WO2012122513A2 (en) * 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
CN104245738B (zh) 2012-04-05 2018-02-02 弗·哈夫曼-拉罗切有限公司 针对人tweak和人il17的双特异性抗体及其用途
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
US20210388096A1 (en) * 2018-10-31 2021-12-16 Astellas Pharma Inc. ANTI-HUMAN Fn14 ANTIBODY

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
HU226787B1 (en) 1996-08-07 2009-10-28 Biogen Idec Inc A tumor necrosis factor related ligand
CA2280231A1 (en) 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
IL135051A0 (en) 1997-10-10 2001-05-20 Genentech Inc Apo-3 ligand polypeptide
JP5550799B2 (ja) 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
JP2003521836A (ja) 1999-03-04 2003-07-15 ビジョン−サイエンシズ・インコーポレイテッド 個別に制御可能な電子シャッター回路を備えた画像センサユニットセル
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
WO2001030374A1 (en) 1999-10-22 2001-05-03 The University Of Pittsburgh Stem cell engraftment-enhancing cellular proteins and their uses
WO2001030429A1 (en) 1999-10-22 2001-05-03 Scimed Life Systems, Inc. Guided injection device
ES2433011T3 (es) 1999-12-20 2013-12-05 Immunex Corporation Receptor TWEAK
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
IL164352A0 (en) 2002-04-09 2005-12-18 Biogen Idec Inc Methods for treating tweak-related conditions
WO2006052926A2 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
CA2597945C (en) 2005-02-17 2016-07-12 Biogen Idec Ma Inc. Treating neurological disorders
BRPI0608012A2 (pt) 2005-03-07 2009-11-03 Genentech Inc método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
CA2609600C (en) * 2005-05-27 2016-11-08 Biogen Idec Ma Inc. Tweak binding antibodies
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
CR20110462A (es) 2011-09-21
SG175005A1 (en) 2011-11-28
NZ594347A (en) 2012-09-28
IL214355A0 (en) 2011-09-27
US8883976B2 (en) 2014-11-11
MA33097B1 (fr) 2012-03-01
US20120083015A1 (en) 2012-04-05
JP2012521771A (ja) 2012-09-20
ECSP11011362A (es) 2011-10-31
CN102369219A (zh) 2012-03-07
EP2414398A2 (en) 2012-02-08
WO2010115555A2 (en) 2010-10-14
US20100255008A1 (en) 2010-10-07
PE20120577A1 (es) 2012-05-23
EP2597104A1 (en) 2013-05-29
US20120207750A1 (en) 2012-08-16
JP5596777B2 (ja) 2014-09-24
KR101344611B1 (ko) 2013-12-30
CA2756245A1 (en) 2010-10-14
AR076020A1 (es) 2011-05-11
WO2010115555A3 (en) 2011-01-06
MX2011010117A (es) 2011-10-14
US8093006B2 (en) 2012-01-10
TWI423815B (zh) 2014-01-21
US8852887B2 (en) 2014-10-07
RU2011143903A (ru) 2013-05-10
AU2010233997A1 (en) 2011-08-18
KR20110122868A (ko) 2011-11-11
CO6362025A2 (es) 2012-01-20
BRPI1014867A2 (pt) 2016-04-12
TW201039847A (en) 2010-11-16
CL2011002452A1 (es) 2012-03-23
SG10201404107SA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
UA105520C2 (uk) Антитіла до людського tweak та їхнє застосування
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
NZ600262A (en) Anti-her3 antibodies and uses thereof
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
UA111818C2 (uk) Антитіло проти csf-1r
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MY177062A (en) Cd37-binding molecules and immunoconjugates thereof
MY156458A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
UA100874C2 (en) Bivalent bispecific antibodies
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
NZ600005A (en) Antibodies against human angiopoietin 2
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
NZ601271A (en) Cd127 binding proteins
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof